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Abstract: This review describes and summarizes the available evidence related to the treatment 
and management of Barth syndrome. The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) standards were used to identify articles published between 
December 2004 and January 2015. The Cochrane Population, Intervention, Control, Outcome, 
Study Design (PICOS) approach was used to guide the article selection and evaluation process. 
Of the 128 articles screened, 28 articles matched the systematic review inclusion criteria. The 
results of this review indicate the need for a flexible and multidisciplinary approach to manage 
the symptoms most commonly associated with Barth syndrome. It is recommended that a com-
prehensive care team should include individuals with Barth syndrome, their family members 
and caregivers, as well as medical, rehabilitative, nutritional, psychological, and educational 
professionals. The evidence for specific treatments, therapies, and techniques for individuals 
with Barth syndrome is currently lacking in both quality and quantity.
Keywords: Barth syndrome, rare disorders, rehabilitation, cardiac, systematic review
Introduction
Barth syndrome is a rare X-linked genetic disorder first described by Dr Peter G Barth 
in 1983.1 It is caused by mutations in the TAZ gene, which is known to encode for the 
protein tafazzin. Tafazzin plays an important role in the remodeling of cardiolipin, 
a component of the mitochondrial membrane necessary for maintaining mitochon-
drial structure as well as for mitochondrial apoptosis and functioning of the electron 
transport chain.2,3 Heart failure is the most common clinical feature identified at birth 
and is the leading cause of death in infants with Barth syndrome. The most common 
cardiac features of Barth syndrome include dilated cardiomyopathy, left ventricular 
non-compaction, endocardial fibroelastosis, and serious disturbances of heart rhythm 
such as ventricular fibrillation or tachycardia.4 Sepsis due to neutropenia may also be 
present at birth and is the second leading cause of infant mortality in Barth syndrome.5 
Though survival past infancy is now common in Barth syndrome, cardiovascular and 
hematological features (ie, neutropenia) in addition to 3-methylglutaconic aciduria 
often continue throughout the individual’s lifespan.6
Clinical presentation of Barth syndrome also includes neuromuscular features 
such as skeletal myopathy, hypotonia, delayed motor milestones, exercise intolerance, 
and abnormal fatigability.7 Growth delay is common in childhood; however, catch-up 
growth often occurs during late adolescence with achievement of normal adult height 
in most boys. Often in Barth syndrome, there is the presence of sensory or oral–
motor feeding problems, nutritional deficiencies, and episodic or chronic diarrhea.8,9 
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Specific feeding-related behaviors include difficulty transi-
tioning to solid foods, frequent gagging or difficulty swal-
lowing, and a strong preference for salty or spicy foods while 
rejecting many other foods eaten by the family.10 There is no 
definitive cognitive or neurological profile associated with 
Barth syndrome, though mild learning disabilities, attention 
deficits, visual spatial deficits, and auditory processing dif-
ficulties have been reported.7,9,11
Considering that Barth syndrome is a multisystem dis-
order, it may be first identified by many different specialists 
or generalists.7 While there is currently no cure for Barth 
syndrome, management of clinical features is possible in 
many cases. Subsequently, individuals with Barth syndrome 
are likely to interact with a wide range of health care profes-
sionals throughout the course of their lifespan in order to 
address the myriad of symptoms associated with the disorder. 
The purpose of this review was to identify interventions that 
are being used to manage symptoms of the disorder and to 
evaluate the evidence for these interventions related to health 
and function-related outcomes.
Methods
Prior to initiating a literature search, a protocol using the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement was established. Five 
databases were strategically searched: PubMed, CINAHL, 
Physiotherapy Evidence Database, Dentistry and Oral 
 Sciences Source, and ProQuest index of Dissertation and 
Theses. This initial search was followed by secondary selec-
tion of articles based on a review of references in relevant 
articles and articles published online by the Barth Syndrome 
Foundation. Following PRISMA guidelines, titles of all 
articles were reviewed for appropriateness, followed by a 
review of relevant abstracts and appraisal of full-text articles.12 
Selection was based on preestablished inclusion and exclusion 
criteria (the information is described in the paragraph below). 
The search strategy was initiated using the following question: 
What treatments, therapies, or techniques are recommended 
for the management of symptoms seen in males with Barth 
syndrome? Search terms included Barth AND Syndrome. 
Only articles published in the last 10 years (December 
2004–January 2015) were considered; nonelectronic sources 
of literature were not considered and only those articles writ-
ten in English were appraised.
The population was specifically defined as males with a 
diagnosis of Barth syndrome. Studies using in vitro methods 
or models (eg, rodent or yeast models) were not considered. 
To meet the inclusion criteria for intervention, each publica-
tion needed to report on the use of a treatment, therapy, or 
technique to improve the health, well-being, or level of func-
tioning for an individual with Barth syndrome. Interventions 
focused on end-of-life care were not considered. No com-
parative intervention or population was required. The studies 
included were required to assess outcomes relevant to the 
management of symptoms commonly seen in Barth syndrome 
including, but not limited to, cardiac function, feeding/eat-
ing, nutrition, motor skill development, education, growth, 
and fatigue. The following standards were used for assessing 
the levels of evidence and to evaluate the study design and 
quality of the reviewed articles:
•	 Level I: systematic reviews, meta-analyses, randomized 
controlled trials
•	 Level II: two groups, nonrandomized studies (eg, case– 
control)
•	 Level III: one group, nonrandomized (eg, before and 
after, pretest and posttest)
•	 Level IV: descriptive studies that include analysis of 
outcomes (single-subject design, case series)
•	 Level V: case reports and expert opinion that include nar-
rative literature reviews and consensus statements.13,14
Results
Initial search strategies of the five databases yield 309 articles, 
with an additional 16 records identified through reference 
review and supplemental searches (Figure 1). After duplicates 
were removed (n=19) and titles were screened for relevance, 
a total of 129 articles remained.2–11,15–133 Within the screened 
publications, descriptive studies, case reports, narrative 
reviews, consensus statements, and expert opinion articles 
were represented. Of the 129 abstracts screened, 86 were 
excluded with reasons, while 17 appeared to match the 
Cochrane Population, Intervention, Control, Outcome, Study 
Design (PICOS) inclusion criteria. An additional 27 articles 
did not have enough information in the abstract to justify 
exclusion, received the designation of “maybe”, and were 
included in the next phase of the review. A comprehensive 
list of the reviewed abstracts with rationale for exclusion is 
presented in Table 1. Based on established exclusion crite-
ria, 24 studies did not meet population criteria (28.6%) and 
71 studies did not fulfill the intervention criteria (84.5%). 
Among the abstracts reviewed, there were none that met both 
population and intervention criteria but were excluded due 
to irrelevant outcome measures.
A total of 44 articles were assessed for eligibility through 
a full-text review. Each of the 44 articles was read and 
evaluated based upon the preestablished inclusion/ exclusion 
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criteria and level of evidence rating. Sixteen articles did 
not meet inclusion criteria and were therefore excluded 
(Table 2). Twenty-eight studies met all inclusion criteria; 
two articles were ranked at Level IV and 26 were ranked 
at Level V. Table 3 identifies the characteristics of all the 
28 articles meeting inclusion criteria, including all PICOS 
components.
Study design
Of the 28 articles selected for this systematic review, 15 were 
case reports,17,21,39,54,60,69,70,84,85,91,101,105,113,114,131 six were litera-
ture reviews,2,3,7,19,47,82 and five were fact sheets.8,20,23,24,26 The 
selected articles also included one descriptive cohort study6 
and one descriptive comparison design.112 Of the 28 articles 
included in this review, only two used statistical analysis 
procedures for the analysis of outcomes. Rigaud et al used 
descriptive and multivariate statistics in a natural history 
cohort study of 22 individuals with Barth syndrome.6 In this 
paper, the Kaplan–Meier method was used to estimate sur-
vival rates and survival was compared between groups of indi-
viduals based on birth year using a log-rank test. Storch et al 
compared a sample of 34 boys with Barth syndrome with 22 
healthy male controls.112 Independent sample t-tests were 
used to compare the two groups on a variety of psychosocial 
outcomes. In this study, the alpha level for significance was 
set at P,0.05; no corrections were made for the possibility 
of type I error with multiple t-tests.
Population
Across all the 28 reviewed articles, 74 males with the diag-
nosis of Barth syndrome were enrolled. The sample varied in 
ethnic origin with representation from American, European, 
and Asian countries. Case reports described the clinical 
courses of individuals with Barth syndrome ranging in age 
from birth to 30 years.
Interventions
Medical interventions
Medical interventions were the most common interventions 
reported, with 23/28 articles reporting on the use of prescription 
Records identified through initial
database search
(n=309)
Records after duplicates removed
(n=291)
Abstracts excluded with
reasons
(n=85)
Abstracts screened
(n=129)
Studies included in
systematic review
(n=28)Inc
lu
d
ed
E
lig
ib
ili
ty
S
cr
ee
n
in
g
Id
en
ti
fi
ca
ti
o
n
Full-text articles
assessed for eligibility
(n=44)
Full-text articles
excluded with reasons
(n=16)
Records eliminated
based on title
(n=162)
Additional records identified
through other sources
(n=16)
Figure 1 PRISMA flow diagram.
Note: Articles identified, screened, eligible, and included in this systematic review.
Abbreviation: PRiSMA, Preferred Reporting items for Systematic Reviews and Meta-Analyses.
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Table 1 Master citation table of reviewed abstracts
Citation Level of 
evidence
Include 
yes/no
Maybe 
(explain)
If no, 
reason to 
exclude
Acehan et al15 iv No P, iT
Acehan et al16 iv No P
Aljishi and Ali17 v iT
Ances et al18 v Yes
Aprikyan and Khuchua19 v iT
Avery20 v Yes
Bachou et al21 v iT
BSF22 v No iT
BSF23 v Yes
BSF24 v Yes
BSF25 v No iT
Bowen et al26 v Yes
Bowron et al27 iv No iT
Bowron et al28 iv No iT
Brady et al29 v No iT
Brandner et al30 iv No P, iT
Cade et al31 iv No iT
Chang et al32 v No iT
Chicco and Sparagna33 v No iT
Clarke et al7 v Yes
Claypool et al34 iv No P, iT
Claypool et al35 iv No iT
Claypool et al36 iv No P
Day et al37 iv No iT
Debnath and Addya38 iv No iT
Dedieu et al39 v Yes
DiMauro40 v No iT
DiMauro and Gurgel-
Giannetti41
v No iT
Donati et al42 v No iT
Fan et al43 v No iT
Feillet-Coudray et al44 v P, iT
Ferri et al5 v iT
Finsterer45 v P, iT
Finsterer46 v No iT
Finsterer and Frank47 v Yes
Finsterer and Stöllberger48 v Yes
Finsterer and Stöllberger49 v iT
Finsterer and Stöllberger50 v No P, iT
Finsterer et al51 v iT
Finsterer et al52 iv No iT
Finsterer et al53 v No iT
Folsi et al54 v iT
Garratt et al4 v iT
Gerbert et al55 v No iT
Gilbert-Barness and  
Barness56
v No iT
Gonzalez57 iv No iT
Gonzalvez et al58 iv No iT
Gonzalvez et al59 iv No P
Hanke et al60 v Yes
Hastings et al61 v No iT
Hauff62 iv No iT
Hauff and Hatch63 v No iT
Hauff and Hatch64 iv No P
(Continued)
Table 1 (Continued)
Citation Level of 
evidence
Include 
yes/no
Maybe 
(explain)
If no, 
reason to 
exclude
Honzik et al65 iv iT
Houtkooper et al66 iv No iT
Houtkooper et al67 iv No iT
Houtkooper and vaz68 v No iT
Huang et al69 v iT
Huhta et al70 v iT
Jefferies3 v Yes
Joshi71 iv No P
Karkucinska- 
wieckowska et al72
iv No iT
Kelley8 v Yes
Kim et al73 v No iT
Kirwin et al74 v No iT
Kirwin et al75 v No iT
Kleefstra et al76 v No P
Kulik et al77 iv iT
Lamari et al78 v No P
Li et al79 iv No P, iT
Makaryan et al80 iv No P
Malhotra et al81 iv No P
Malhotra et al82 v iT
Man et al83 v No iT
Mangat et al84 v Yes
Marziliano et al85 v iT
Mayr86 v No iT
Mazurová et al87 v No iT
Mazzocco et al11 iv No iT
McCanta et al88 v iT
McKenzie et al89 iv No iT
Mejia et al90 v No P, iT
Momoi et al91 v Yes
Monteiro et al92 v P
Moric-Janiszewska and 
Markiewicz-Łoskot93
v No iT
Osman et al94 iv No P
Poloncová and Griač95 v No P
Raches and Mazzocco96 iv No iT
Raja and Greenberg97 v No iT
Raval and Kamp98 v No P, iT
Reynolds et al9 iv No iT
Reynolds et al10 (in press) iv No iT
Rigaud et al6 iv iT
Roberts et al99 iv No iT
Ronvelia et al100 v No iT
Sabater-Molina et al101 v iT
Saini-Chohan et al102 v No iT
Schlame and Ren103 v No iT
Schug et al104 v No iT, P
Singh et al105 v iT
Soustek et al106 iv No P
Sparagna and Lesnefsky107 v Yes
Spencer et al108 iv No iT
Spencer et al109 iv No iT
Spencer et al110 v No iT
Steward et al111 v No iT
(Continued)
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angiotensin- converting enzyme inhibitors such as captopril; 
beta- adrenoceptor blockers (β-blockers) such as carvedilol were 
also reported to be frequently used for the treatment of hyperten-
sion, CHF, and/or arrhythmia.2,3,6,7,17,21,23,54,69,70,82,85,91,101,113
In addition to pharmacological therapy to address heart 
failure, surgical techniques were also identified. Case reports 
indicated cardiac transplants in six individuals with Barth 
syndrome,60,84,105 while two additional case reports indicated 
mitral valve replacement or valvuloplasty.69,131 Three case 
reports39,60,105 and one cohort study6 identified the use of a ven-
tricular assistance device (eg, the Berlin Heart EXCOR) as a 
successful bridge to cardiac transplant. An implantable cardio-
verter defibrillator was utilized in one case to prevent sudden 
death due to life-threatening ventricular arrhythmias.70
Medical management of neutropenia was most frequently 
accomplished with the use of granulocyte colony-stimulating 
factor (G-CSF), as reported in four case reports.21,54,60,70 In 
their cohort study of 22 individuals with Barth syndrome, 
Rigaud et al indicated that G-CSF was used in six patients, 
with two individuals receiving long-term G-CSF therapy and 
the other four using G-CSF “on demand” when an infection 
occurred.6 In the same study, four individuals also received 
antibiotic prophylaxis for the treatment of infections second-
ary to neutropenia.
Dietary interventions
Dietary interventions were identified in 11/28 of the reviewed 
articles. The use of oral carnitine supplementation (eg, L- 
carnitine) was identified in one case report,17 one fact 
sheet,23 and two literature reviews.7,47 Dietary supplemen-
tation with argentine was recommended in two literature 
reviews7,3 and one cohort study.6 Other nutritional supple-
ments recommended as dietary interventions in the Barth 
population included cornstarch given before bedtime,7,20 
parenteral amino acid nutrition or intravenous supplemental 
amino acids,8,24 magnesium supplementation,114 potassium 
supplementation,8,23,24 and daily multivitamins.23,24 Storch 
et al noted that boys with Barth syndrome may also need a 
special diet at school, suggesting the need for dietary inter-
ventions across multiple settings.112
Feeding aids and strategies
Feeding aids were identif ied in 5/28 of the reviewed 
articles. Nasogastric and gastronomy tubes were recom-
mended in cases where boys with Barth syndrome could 
not take adequate amounts of food or drink by mouth and 
therefore needed nutrients to be placed directly into the 
stomach.6,7,24,70,91 Other feeding aids recommended by the 
Barth Syndrome Foundation24 included preemie nipples, Hab-
Table 1 (Continued)
Citation Level of 
evidence
Include 
yes/no
Maybe 
(explain)
If no, 
reason to 
exclude
Storch et al112 iv iT
Sweeney et al113 v iT
Tajima et al114 v Yes
Takeda et al2 v Yes
Takeda et al115 v No iT
Tikhomirov et al116 v No iT
Towbin117 v No P, iT
valianpour et al118 iv No iT
van Raam and Kuijpers119 v No iT
van werkhoven et al120 iv No P, iT
vernon et al121 iv No iT
wan et al122 iv iT
wang et al123 iv iT
whited et al124 iv No P, iT
wilson et al125 iv No iT
wortmann et al126 v No iT
Xing et al127 iv No iT
Xu et al128 iv No P
Xu et al129 iv No iT
Ye et al130 v No iT
Yen et al131 v iT
Zaragoza et al132 v No iT
Zweigerdt et al133 v P, iT
Notes: P indicates population that does not include human males with Barth 
syndrome; IT indicates that intervention used cannot be classified as a medical or 
rehabilitative treatment, therapy, or technique used to improve health, well-being, 
or level of functioning.
Abbreviation: BSF, Barth Syndrome Foundation.
Table 2 Articles excluded after full-text review
Citation Level of  
evidence
Reason to 
exclude
Ances et al18 v iT
Feillet-Coudray et al44 iv P
Ferri et al5 v iT
Finsterer45 v P
Finsterer and Stöllberger48 v P, iT
Finsterer and Stöllberger49 v P
Finsterer et al51 v P
Garratt et al4 v iT
Honzik et al65 iv iT
Kulik et al77 iv iT
McCanta et al88 v iT
Monteiro et al92 v P
Sparagna and Lesnefsky107 v P
wan et al122 iv P
wang et al123 iv P
Zweigerdt et al133 v P
Notes: P indicates population that does not include human males with Barth 
syndrome; IT indicates that intervention used cannot be classified as a medical or 
rehabilitative treatment, therapy, or technique used to improve health, well-being, 
or level of functioning.
medications and/or surgical techniques. Medical management 
of heart failure often used a polypharmacological approach. 
Cardiac hypertension and congestive heart failure (CHF) 
were frequently reported to be treated with cardiac glyco-
sides such as digoxin, diuretics such as furosemide, and 
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ermann Feeders®, and Supplemental Nutrition Systems™. 
Feeding strategies for boys with Barth syndrome were also 
described in cases where the child had strong food and eat-
ing preferences (eg, picky eaters or sensory sensitivities). 
These strategies included giving the child control over food 
choices or having the option to spit something out, consum-
ing small portions of food throughout the day instead of 
eating three large meals, and slowly introducing new foods 
into the child’s diet.24
Rehabilitative
Limited rehabilitative interventions were identified in 
this review. One case study105 and one literature review47 
identified physical therapy (ie, physiotherapy) as a possible 
intervention to improve muscle weakness and tone in boys 
with Barth syndrome. Another literature review acknowl-
edged that mobility aids such as wheelchairs may be used 
to conserve energy.7
educational
Storch et al reported a significant need for academic accom-
modations for boys with Barth syndrome as compared to 
healthy male controls.112 Specific accommodations identified 
in this study were classroom seating changes, rest periods, 
schedule adjustments, note takers, extra books for home use, 
alternative assignments, extra tutorials, use of tape record-
ers, and peer mentors. In addition, some boys with Barth 
syndrome may need medication administration at school. As 
noted by Clarke et al, approximately 33% of boys with Barth 
syndrome require some form of special education.7
Psychological
In addition to academic and educational supports, Storch 
et al found that out of the 34 boys – with Barth syndrome – 
surveyed, 26% were monitored by a school psychologist, 
while 22% had close contact with a guidance counselor.112 
No other psychological interventions were identified in the 
28 articles included in this review.
Outcomes
The most frequent outcomes reported in the 28 reviewed 
articles were related to the core features of Barth syndrome, 
which are cardiac complications (eg, CHF, hypertension, and 
arrhythmia) and neutropenia. Specific outcomes related to 
heart function included improvement of ejection fraction on 
echocardiogram,17 progressive improvement of left ventricu-
lar function,85 improvement in cardiomegaly with reduced 
pulmonary edema,91 and decreased incidence of heart failure6 
with the use of cardiac medications. However, since most 
articles reported on the use of multiple medications simul-
taneously, the individual contributions of each medication 
or medication type are indistinguishable from the overall 
effects of the medication regime. In contrast, neutropenia 
was primarily treated using G-CSF, and therefore outcomes 
such as increased neutrophil count and reduced infection can 
be more specifically linked with this medical treatment.6,21 
Interestingly, the simultaneous use of multiple drugs 
(polypharmacy) was questioned in one review, indicating 
that coadministration of contraindicated medications may 
prove to be life threatening in some children with Barth 
syndrome.82
Objective outcomes related to dietary interventions or 
use of feeding aids were limited in this systematic review. 
While one literature review suggested that carnitine defi-
ciency in Barth syndrome may be ameliorated by means of 
substitution,47 other articles suggested no significant benefit 
with the use of carnitine supplements.7,17,23 Similarly, one pub-
lished review7 and one case report84 suggested that there is no 
evidence for the use of pantothenic acid supplements in this 
population. Magnesium supplementation was utilized in one 
case report of an 18-year-old male with Barth syndrome.114 
In this report, magnesium supplementation led to a slight 
improvement in muscle strength and normalization of serum 
magnesium levels. Specific outcomes data related to caloric 
intake, weight gain, and/or growth were not reported in the 
other reviewed articles which utilized dietary interventions, 
feeding aids, or feeding strategies.
Rehabilitative outcomes were also limited in this review. 
Singh et al reported on a 7-month-old African-American 
male with Barth syndrome whose muscle tone improved 
with physical therapy; however, the frequency and duration 
of physical therapy were not reported, nor were any specific 
measures of muscle strength or tone.105 In line with this out-
come, Finsterer and Frank indicated in their 2013 review that 
physiotherapy may help to improve muscle weakness in boys 
with Barth syndrome.47 Interestingly, Takeda et al argued in 
their review of the literature that no treatment is needed for 
hypotonia because it usually resolves spontaneously.2
No outcomes related to educational or psychological 
interventions were reported.
Discussion
Medical management of Barth syndrome
The interventions and outcomes identified in this review 
reinforce that treatment of medical complications associ-
ated with Barth syndrome is of primary importance in this 
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population. However, the types of articles available for this 
systematic review represent reports that are not based on 
scientific analysis of clinical outcomes. Of the 28 reviewed 
articles, 15 were case reports. While case reports have a role 
in medical literature, particularly for detecting novelties and 
describing unique cases, findings from case reports often lack 
generalizability and are reliant upon the author’s memory of 
events or availability of information in medical records.134
Though lacking direct evidence, the accumulation of 
descriptive data from case reports and expert clinical opinion 
suggest that cardiac medications (eg, β-blockers, angiotensin-
converting enzyme inhibitors) can be used to alleviate symp-
toms of heart failure and prolong life in boys with Barth 
syndrome. In addition, several sources reported increased 
levels of circulating neutrophils following G-CSF treatment, 
suggesting that G-CSF, possibly combined with appropriate 
prophylactic antibiotics, is the best available treatment for neu-
tropenia in this population.19,21,70 While neutropenia appears 
to respond well to G-CSF, Rigaud et al noted that 2 of the 22 
Barth patients in their cohort study had episodes of severe 
infection while on G-CSF therapy.6 It is also important to note 
that some medications, either in isolation or coadministered 
with other medications, may cause symptoms to worsen, 
and therefore starting or stopping of any new medications or 
increasing the dosage of the existing ones should be closely 
monitored in boys with Barth syndrome.23
While several successful surgeries, including cardiac 
transplants, were reported in the 28 reviewed articles,60,84,105 
none of the articles provided data on how many boys with 
Barth syndrome failed to survive the surgery or what was the 
long-term survival rates post discharge. Since journals often 
prefer publication of cases with positive outcomes, there is 
a risk in overstating or generalizing the surgical outcomes 
gleaned in this review.134
Despite the lack of specific outcomes in this review, it is 
clear that medical management of Barth syndrome is essential 
for growth and survival. Medical team members involved in 
the care of boys with Barth syndrome may include special-
ists in cardiology, hematology, metabolism, endocrinology, 
neurology, and genetics, as well as developmental pediatri-
cians and primary care physicians.
Feeding and dietary interventions for 
Barth syndrome
The literature supporting nonmedical interventions for 
Barth syndrome is much scarcer. While it has been identi-
fied that feeding issues are stressful for families of boys 
with Barth syndrome, very little research has been directed 
toward interventions that support feeding behaviors or 
nutritional concerns.9,10 Further, there does not appear to be 
consensus about which nutritional supplements are effective 
in this population or what process should go into the selection 
of a supplemental regime.
Given the complexity of feeding and nutritional issues 
in boys with Barth syndrome, multiple disciplines may 
be involved in the management of these clinical features. 
 Dietitians and nutritional specialists will likely work closely 
with medical doctors, including metabolic specialists, to 
determine what and how much food/liquid the child should 
be consuming. Decisions about the placement of nasogastric 
tubes or other long-term enteral nutritional support will likely 
be made by a team of individuals familiar with the specific 
child and familiar with the complexities of Barth syndrome. 
Throughout the lifespan of a boy with Barth syndrome, the 
needs of the child and the family will likely require con-
sultation or intervention by a variety of other health care 
professionals. During infancy, lactation consultants, pediatric 
nurses, and occupational therapists may work with families in 
order to facilitate good positioning for breastfeeding and rec-
ommend appropriate feeding aids and strategies to assist the 
child with oral sucking and self-regulation during the feeding 
process. When the child begins transitioning to solid foods, 
rehabilitative professionals (ie, physical therapists, occupa-
tional therapists, and speech and language pathologists) may 
be consulted for issues related to proper positioning, coordi-
nation of chewing and swallowing, or sensory sensitivities 
leading to picky eating patterns. As the child grows, nutritional 
concerns related to growth will likely become important and 
ongoing case management with the medical team may be 
necessary. During the school years, special dietary or feeding 
needs may need to be documented on the child’s individual-
ized education plan and consultation between the school team 
and medical team may be required. Since eating is a big part of 
normal socialization patterns, practitioners should be mindful 
of the need for children, adolescents, and adults with Barth 
syndrome to participate in these types of activities as part of 
their overall psychosocial health.
interventions to support participation 
and well-being
This systematic review identified a relative gap in the litera-
ture in regard to the interventions that support the participa-
tion and well-being of boys with Barth syndrome and their 
families. Physical therapy was identified as one rehabilitative 
service that could potentially help enhance muscle strength 
and tone; however, it was unclear from the review whether 
these improvements in strength and tone led to increased play 
with peers, greater participation due to lack of fatigue, or an 
Journal of Multidisciplinary Healthcare 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
355
Successful management of Barth syndrome
improvement in self-concept or self-esteem. Research using 
mouse models of Barth syndrome are beginning to provide 
insights into the physiological benefits of exercise and endur-
ance training;135 however, translation of these findings into 
practice are nonexistent. As basic science research begins to 
work its way from bench to bedside, it will be important for 
researchers and clinicians alike to focus on the functional and 
participation benefits of exercise in addition to changes in 
muscle physiology.
Finally, this review did not identify any currently 
researched interventions to address the psychosocial needs 
of boys with Barth syndrome and their families. As noted by 
Storch et al, youth with Barth syndrome tend to have more 
internalizing and externalizing symptoms, social problems, 
and loneliness compared to healthy children; in addition, 
they rate their overall quality of life much lower than that of 
healthy controls and other children with cardiac problems.112 
Parents of boys with Barth syndrome also report higher stress 
levels compared to parents of health controls. Psychologists, 
licensed clinical social workers, occupational therapists, 
and other mental health professionals may be able to help 
children and families with these issues through a variety of 
therapeutic interventions. There is a current need to examine 
the usefulness and applicability of these types of services in 
the Barth population.
Conclusion
This systematic review highlights the paucity of objective, 
high-level evidence supporting interventions for males with 
Barth syndrome. While case reports and literature reviews 
on this rare disorder are important contributions to the lit-
erature, future studies should aim to include systematic and 
objective analyses of outcomes using research designs with 
methodological rigor. This level of research is needed across 
multiple disciplines in order to develop best practices for the 
management of the symptoms most commonly associated 
with the Barth syndrome. Clinically, it is recommended that 
a comprehensive care team be established, which includes 
individuals with Barth syndrome, their family members and 
caregivers, as well as medical, rehabilitative, nutritional, 
psychological, and educational professionals. While medical 
management of symptoms that preserves life is of primary 
importance, services that enhance the child’s and family’s 
quality of life and participation should also be included as 
part of the individual’s care plan.
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